Kleanthis G. Xanthopoulos, Ph.D.
Board Member, President and CEO
Born in 1958. Joined IRRAS in 2015.
Member of the Board since 2015.
Other current assignments:
Board member of ZosanoPharma Inc., and Sente Inc. Management member in Cerus Advisors DMCC and President of Helios Inc.
Education and relevant experience:
Kleanthis G. Xanthopoulos holds an M.Sc. and a Ph.D. in Molecular Biology from
Stockholm University and was an Associate Professor at Karolinska Institute in
Kleanthis G. Xanthopoulos has more than 25 years’ experience from operational positions in the life science sector. Kleanthis G. Xanthopoulos also has extensive experience as an investor in life science companies in the United States and Europe and has founded three life science companies before joining IRRAS, of which two have been listed at Nasdaq (Anadys Pharmaceuticals, Inc. which was acquired by F. Hoffmann-La Roche Inc. in 2011, and Regulus Therapeutics Inc). Kleanthis G. Xanthopoulos has also financed and brokered numerous creative strategic alliance and partnership deals with large pharmaceutical partners. He is an Onassis Scholar and has received numerous awards, including E&Y Entrepreneur of the Year in San Diego and CEO of the Year in San Diego.
Shareholding in IRRAS: 842,878 shares.
Holding of warrants: 1,275,000 warrants under the 2016/2025 warrant program and 43,237 warrants under the 2018/2022 warrant program.
Kleanthis G. Xanthopoulos is not independent in relation to the company and
its management and not in relation to major shareholders.